Inventor · disambiguated record

Christoph Schraeder

Also filed as: SCHRAEDER CHRISTOPH

5 granted patents·39 pending applications·0 citations·filing 2021–2024

73Inventor score

Technology areasA61K G01N

Files withIMMATICS BIOTECHNOLOGIES GMBH44

Top patents by PatentIndex Score

44 records

0190US2024239865A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0290US2024166713A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0390US2024166717A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0490US2024239866A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0590US2024166715A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0690US2024247045A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0790US2024166716A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0890US2024239867A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
0990US2024166714A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1090US2024254191A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1190US2024166712A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1289US2024158460A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1389US2024117004A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1489US2024067697A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1589US2024132570A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1689US2024218044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1789US2024075119A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
1889US2024158461A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
1989US2024109949A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2089US2024247044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2189US2024279306A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2289US2024150430A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2389US2024150429A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
2489US2024117003A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2589US2024141013A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2688US11969464B2Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 30, 2024·0 cites·20 claims
2788US2024016910A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2888US2024016912A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
2988US2024024441A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3088US2024016913A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3188US2024016906A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3288US2024024440A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3388US2024016907A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3488US2023414734A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3588US2024016909A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3688US2024016911A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3788US2024075118A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
3887US11952409B2Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary classIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·20 claims
3987US11904003B2Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Feb 20, 2024·0 cites·20 claims
4081US11891427B2Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 6, 2024·0 cites·20 claims
4181US11833195B2Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 5, 2023·0 cites·20 claims
4266US2024131131A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
4358US2023024554A1Method of characterizing the binding characteristics between a peptide of interest and mhc moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4457US2022283176A1Method for the absolute quantification of mhc moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Christoph Schraeder files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →